Dario Giugliano

Dario Giugliano

Auto-generated profile, based on publicly available information

Dario Giugliano

Department of Advanced Medical and Surgical Sciences University of Campania “Luigi Vanvitelli” Naples Italy

Research Focus & Metrics

Academic Career Length

51Years (1976-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2004 in JAMA
Verified
Journal Article
Open access
PDF file
KEKatherine Esposito
Katherine Esposito
RMRaffaele Marfella
Raffaele Marfella
MCMiryam Ciotola
Miryam Ciotola
CPCarmen Di Palo
Carmen Di Palo
FGFrancesco Giugliano
Francesco Giugliano
DGDario Giugliano
Dario Giugliano
The metabolic syndrome consists of a constellation of factors that increase the risk of cardiovascular disease and type 2 diabetes. Recent estimates indicate that the metabolic syndrome is highly prevalent in the United States, with an estimated 24% of the adult population affected.1 Its clinical identification is based on measures of abdominal obesity, atherogenic dyslipidemia, elevated blood pressure, and glucose intolerance.2 The etiology of this syndrome is largely unknown but presumably represents a complex interaction between genetic, metabolic, and environmental factors including diet.3,4 Several recent studies also suggest that a proinflammatory state is one component of the metabolic syndrome.5-8 Moreover, evidence has accumulated indicating that low-grade inflammation is associated with endothelial dysfunction.9,10

15 October 2002 in Circulation
Verified
Journal Article
Closed access
PDF file
KEKatherine Esposito
Katherine Esposito
FNFrancesco Nappo
Francesco Nappo
RMRaffaele Marfella
Raffaele Marfella
GGGiovanni Giugliano
Giovanni Giugliano
FGFrancesco Giugliano
Francesco Giugliano
DGDario Giugliano
Dario Giugliano
Background— Circulating levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) are elevated in diabetic patients. We assessed the role of glucose in the regulation of circulating levels of IL-6, TNF-α, and interleukin-18 (IL-18) in subjects with normal or impaired glucose tolerance (IGT), as well as the effect of the antioxidant glutathione. Methods and Results— Plasma glucose levels were acutely raised in 20 control and 15 IGT subjects and maintained at 15 mmol/L for 5 hours while endogenous insulin secretion was blocked with octreotide. In control subjects, plasma IL-6, TNF-α, and IL-18 levels rose ( P <0.01) within 2 hours of the clamp and returned to basal values at 3 hours. In another study, the same subjects received 3 consecutive pulses of intravenous glucose (0.33 g/kg) separated by a 2-hour interval. Plasma cytokine levels obtained at 3, 4, and 5 hours were higher ( P <0.05) than the corresponding values obtained during the clamp. The IGT subjects had fasting plasma IL-6 and TNF-α levels higher ( P <0.05) than those of control subjects. The increase in plasma cytokine levels during the clamping lasted longer (4 hours versus 2 hours, P <0.01) in the IGT subjects than in the control subjects, and the cytokine peaks of IGT subjects after the first glucose pulse were higher ( P <0.05) than those of control subjects. On another occasion, 10 control and 8 IGT subjects received the same glucose pulses as above during an infusion of glutathione; plasma cytokine levels did not show any significant change from baseline after the 3 glucose pulses. Conclusions— Hyperglycemia acutely increases circulating cytokine concentrations by an oxidative mechanism, and this effect is more pronounced in subjects with IGT. This suggests a causal role for hyperglycemia in the immune activation of diabetes.

1 March 1996 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
DGDario Giugliano
Dario Giugliano
ACAntonio Ceriello
Antonio Ceriello
Giuseppe PaolissoGiuseppe Paolisso
Giuseppe Paolisso
Long-term vascular complications still represent the main cause of morbidity and mortality in diabetic patients. Although prospective randomized long-term clinical studies comparing the effects of conventional and intensive therapy have demonstrated a clear link between diabetic hyperglycemia and the development of secondary complications of diabetes, they have not defined the mechanism through which excess glucose results in tissue damage. Evidence has accumulated indicating that the generation of reactive oxygen species (oxidative stress) may play an important role in the etiology of diabetic complications. This hypothesis is supported by evidence that many biochemical pathways strictly associated with hyperglycemia (glucose autoxidation, polyol pathway, prostanoid synthesis, protein glycation) can increase the production of free radicals. Furthermore, exposure of endothelial cells to high glucose leads to augmented production of superoxide anion, which may quench nitric oxide, a potent endothelium-derived vasodilator that participates in the general homeostasis of the vasculature. In further support of the consequential injurious role of oxidative stress, many of the adverse effects of high glucose on endothelial functions, such as reduced endothelial-dependent relaxation and delayed cell replication, are reversed by antioxidants. A rational extension of this proposed role for oxidative stress is the suggestion that the different susceptibility of diabetic patients to microvascular and macrovascular complications may be a function of the endogenous antioxidant status.

9 April 2003 in JAMA
Verified
Journal Article
Closed access
PDF file
KEKatherine Esposito
Katherine Esposito
APAlessandro Pontillo
Alessandro Pontillo
CPCarmen Di Palo
Carmen Di Palo
GGGiovanni Giugliano
Giovanni Giugliano
MMMariangela Masella
Mariangela Masella
DGDario Giugliano
Dario Giugliano
Context: Obesity is an independent risk factor for cardiovascular disease, which may be mediated by increased secretion of proinflammatory cytokines by adipose tissue.Objective: To determine the effect of a program of changes in lifestyle designed to obtain a sustained reduction of body weight on markers of systemic vascular inflammation and insulin resistance.Design and Setting: Randomized single-blind trial conducted from February 1999 to February 2002 at a university hospital in Italy.Patients: One hundred twenty premenopausal obese women (body mass index ≥30) aged 20 to 46 years without diabetes, hypertension, or hyperlipidemia.Interventions: The 60 women randomly assigned to the intervention group received detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity. The control group (n = 60) was given general information about healthy food choices and exercise.Main Outcome Measures: Lipid and glucose intake; blood pressure; homeostatic model assessment of insulin sensitivity; and circulating levels of interleukin 6 (IL-6), interleukin 18 (IL-18), C-reactive protein (CRP), and adiponectin.Results: After 2 years, women in the intervention group consumed more foods rich in complex carbohydrates (9% corrected difference; P<.001), monounsaturated fat (2%; P = .009), and fiber (7 g/d; P<.001); had a lower ratio of omega-6 to omega-3 fatty acids (−5; P<.001); and had lower energy (−310 kcal/d; P<.001), saturated fat (−3.5%; P = .007), and cholesterol intake (−92 mg/d; P<.001) than controls. Body mass index decreased more in the intervention group than in controls (−4.2; P<.001), as did serum concentrations of IL-6 (−1.1 pg/mL; P = .009), IL-18 (−57 pg/mL; P = .02), and CRP (−1.6 mg/L; P = .008), while adiponectin levels increased significantly (2.2 µg/mL; P = .01). In multivariate analyses, changes in free fatty acids (P = .008), IL-6 (P = .02), and adiponectin (P = .007) levels were independently associated with changes in insulin sensitivity.Conclusion: In this study, a multidisciplinary program aimed to reduce body weight in obese women through lifestyle changes was associated with a reduction in markers of vascular inflammation and insulin resistance.

13 October 2012 in Diabetes Care
Verified
Journal Article
Open access
PDF file
KEKatherine Esposito
Katherine Esposito
PCPaolo Chiodini
Paolo Chiodini
ACAnnamaria Colao
Annamaria Colao
ALAndrea Lenzi
Andrea Lenzi
DGDario Giugliano
Dario Giugliano
OBJECTIVE Available evidence supports the emerging hypothesis that metabolic syndrome may be associated with the risk of some common cancers. We did a systematic review and meta-analysis to assess the association between metabolic syndrome and risk of cancer at different sites. RESEARCH DESIGN AND METHODS We conducted an electronic search for articles published through October 2011 without restrictions and by reviewing reference lists from retrieved articles. Every included study was to report risk estimates with 95% CIs for the association between metabolic syndrome and cancer. RESULTS We analyzed 116 datasets from 43 articles, including 38,940 cases of cancer. In cohort studies in men, the presence of metabolic syndrome was associated with liver (relative risk 1.43, P < 0.0001), colorectal (1.25, P < 0.001), and bladder cancer (1.10, P = 0.013). In cohort studies in women, the presence of metabolic syndrome was associated with endometrial (1.61, P = 0.001), pancreatic (1.58, P < 0.0001), breast postmenopausal (1.56, P = 0.017), rectal (1.52, P = 0.005), and colorectal (1.34, P = 0.006) cancers. Associations with metabolic syndrome were stronger in women than in men for pancreatic (P = 0.01) and rectal (P = 0.01) cancers. Associations were different between ethnic groups: we recorded stronger associations in Asia populations for liver cancer (P = 0.002), in European populations for colorectal cancer in women (P = 0.004), and in U.S. populations (whites) for prostate cancer (P = 0.001). CONCLUSIONS Metabolic syndrome is associated with increased risk of common cancers; for some cancers, the risk differs betweens sexes, populations, and definitions of metabolic syndrome.

1 May 2008 in Diabetes
Verified
Journal Article
Open access
PDF file
ACAntonio Ceriello
Antonio Ceriello
KEKatherine Esposito
Katherine Esposito
LPLudovica Piconi
Ludovica Piconi
MIMichael A. Ihnat
Michael A. Ihnat
JTJessica E. Thorpe
Jessica E. Thorpe
DGDario Giugliano
Dario Giugliano
OBJECTIVE—To explore the possibility that oscillating glucose may outweigh A1C levels in determining the risk for cardiovascular diabetes complications. RESEARCH DESIGN AND METHODS—A euinsulinemic hyperglycemic clamp at 5, 10, and 15 mmol/l glucose was given in increasing steps as a single “spike” or oscillating between basal and high levels over 24 h in normal subjects and type 2 diabetic patients. Flow-mediated dilatation, a marker of endothelial function, and plasma 3-nitrotyrosine and 24-h urinary excretion rates of free 8-iso PGF2α, two markers of oxidative stress, were measured over 48 h postclamp. RESULTS—Glucose at two different levels (10 and 15 mmol/l) resulted in a concentration-dependent fasting blood glucose–independent induction of both endothelial dysfunction and oxidative stress in both normal and type 2 diabetic patients. Oscillating glucose between 5 and 15 mmol/l every 6 h for 24 h resulted in further significant increases in endothelial dysfunction and oxidative stress compared with either continuous 10 or 15 mmol/l glucose. CONCLUSIONS—These data suggest that oscillating glucose can have more deleterious effects than constant high glucose on endothelial function and oxidative stress, two key players in favoring cardiovascular complications in diabetes. Concomitant vitamin C infusion can reverse this impairment.